Anti-tumor necrosis factor α F(ab') 2 antibody fragments protect in murine polymicrobial sepsis: Concentration and early intervention are fundamental to the outcome

Inflammation Research

Volumn 55, Issue 9, 2006, Pages 378-384

  Marquez Velasco R ^a   Bojalil, R ^a,c   Buelna, A ^b   Flores Guzman F ^b   Estevez Ramirez, J ^b   Laguna, J ^a   Hernandez A M ^a   Diaz Quinonez A ^b   Paniagua Solis J F ^b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b Laboratorios Silanes SA de CV   (Mexico)

^c DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

Anti TNF ; F(ab') 2 fragments ; Immune response regulation; Polymicrobial sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CULTURE; CECUM; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; LIGATION; MALE; MOUSE; NONHUMAN; SEPSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; BACTEREMIA; CYTOKINES; ESCHERICHIA COLI; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICE; MICE, INBRED BALB C; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEPSIS; STAPHYLOCOCCUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247169134     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-6001-6     Document Type: Article

References (54)

1. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993; 21: S415-22.
2. Erickson SL, de Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372: 560-3.
3. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-67.
4. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
5. Banks TA, Rouse BT, Kerley MK, Blair PJ, Godfrey VL, Kuklin NA et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 1995; 155: 1685-93.
6. Le Hir M, Bluethmann H, Kosco-Vilbois MH, Muller M, di Padova F et al. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med 1996; 183: 2367-72.
7. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-411.
8. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093-8.
9. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992; 22: 1447-54.
10. Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60: 4003-8.
11. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-9.
12. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
13. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136: 4220-5.
14. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985; 135: 2069-73.
15. Lima EC, Garcia I, Vicentelli MH, Vassalli P, Minoprio P. Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice. Infect Immun 1997; 65: 457-65.
16. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029-32.
17. Billiau A, Heremans H, Vandekerckhove F, Dillen C. Anti-interferon-gamma antibody protects mice against the generalized Shwartzman reaction. Eur J Immunol 1987; 17: 1851-4.
18. Car BD, Eng VM, Schnyder B, Ozmen L, Huang S, Gallay P et al. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994; 179: 1437-44.
19. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31.
20. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol 1992; 149: 1666-70.
21. Heinzel FP. The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 1990; 145: 2920-4.
22. Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol 1990; 145: 4185-91.
23. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
24. Ulich TR, Guo KZ, Irwin B, Remick DG, Davatelis GN. Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am J Pathol 1990; 137: 1173-85.
25. Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P et al. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25: 672-6.
26. Lamy M, Deby-Dupont G. Is sepsis a mediator-inhibitor mismatch? Intensive Care Med 1995; 21 Suppl 2: S250-7.
27. Fink MP, Payen D. The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995. Intensive Care Med 1996; 22: 158-65.
28. Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-9.
29. Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Crit Care Med 1993; 21: 1770-6.
30. Ward PA. Mechanisms of endothelial cell killing by H2O2 or products of activated neutrophils. Am J Med 1991; 91: 89S-94S.
31. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-76.
32. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43.
33. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148: 2724-30.
34. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G. Blockade of tumor necrosis factor reduces lipopolyssaccharide lethality but not the lethality of cecal ligation and puncture. Shock 1995; 4: 89-95.
35. Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med 2001; 27: 1169-78.
36. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-5.
37. Andrew S, Titus J. Fragmentation of ImmunoglobulinG. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W (Eds). Current Protocols in Immunology. Vol. 1. John Wiley & Sons, Inc, New York, 2002: 2.8.1-2.8.10.
38. 2 de anticuerpos y un proceso para su preparación. 2005. Mexico patent 230257.
39. 2 Antibody Fragments and a Process for the Preparation Thereof. 2004. US patent 6,709,655 B2.
40. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3: 207-12.
41. Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R. Manual of Clinical Microbiology. 8th ed. Washington, DC. ASM Press; 2003.
42. Pastorino JG, Simbula G, Yamamoto K, Glascott PA Jr, Rothman RJ, Farber JL. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J Biol Chem 1996; 271: 29792-8.
43. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
44. Ghosh S, Latimer RD, Gray BM, Harwood RJ, Oduro A. Endotoxin-induced organ injury. Crit Care Med 1993; 21: S19-24.
45. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323: 86-9.
46. Stuyt RJ, Kim SH, Reznikov LL, Fantuzzi G, Novick D, Rubinstein M et al. Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine 2003; 21: 65-73.
47. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145: 3762-6.
48. Yin K, Gribbin E, Wang H. Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 2005; 24: 396-401.
49. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-81.
50. Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004; 43: 527-9.
51. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004; 38: 58-61.
52. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004; 16: 393-8.
53. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004; 22: 39-53.
54. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.